Esketamine Hydrochloride

New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting, where real-world data from the Company’s proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on advancing the understanding of transcranial magnetic stimulation (TMS) for mental health conditions. NeuroStar-related presentations at CTMSS reflect the Company’s commitment to advancing TMS research and learning from real-world evidence. The Company continues to explore treatment outcomes across diverse patient populations in real-world clinical settings. “The continued expansion of real-world evidence is critical to advancing our understanding of TMS and its role in clinical practice,” said Cory Anderson, Chief Technology Officer at Neuronetics. “These findings reflect the value of combining the industry’s largest real-world TMS database with rigorous scientific analysis to generate meaningful insights that can be shared with the broader mental health community during CTMSS.” The following data will be presented: The Effectiveness of Transcranial Magnetic Stimulation for Major Depressive Disorder: Associations with Age and Biological Sex Poster Presentation Presentation Date: Friday, June 5 th at 4:25 - 5:55 PM ET Real-World Antidepressant Outcomes of Transcranial Magnetic Stimulation in Adolescents Aged 12–14 Poster Presentation Presentation Date: Friday, June 5 th at 4:25 - 5:55 PM ET Keeping Our Patients Better with TMS Maintenance Therapy Plenary VI Presentation Presenter: Linda Carpenter, FCTMSS, MD Presentation Date: Saturday, June 6 th at 10:10 – 10:55 AM ET In addition to its scientific presentations, Neuronetics will participate in the PULSES Course , a hands-on training program at CTMSS, to demonstrate NeuroStar’s navigation capabilities enabled through the Company’s partnership with ANT Neuro. Neuronetics’ participation at CTMSS underscores the Company’s broader commitment to innovation, scientific leadership, and advancing evidence-based treatment options for patients living with depression and other mental health disorders. For more information about NeuroStar TMS Therapy, please visit NeuroStar.com . About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO ® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com . Neuronetics Contact: Investors: Mike Vallie or Mark Klausner ICR Healthcare 443-213-0499 ir@neuronetics.com Media: EvolveMKD 646.517.4220 NeuroStar@evolvemkd.com References 1 The effectiveness of SPRAVATO ® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO ® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO ® . For more important safety information about SPRAVATO ® , please visit spravatohcp.com .

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions Installation complements HOPE's interventional psychiatry platform and aligns with NRx's previously announced clinical trial of NRX-101 in combination with robotic-enabled TMS WEST PALM BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its wholly-owned subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has become the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System. The system has been installed at HOPE's West Palm Beach, Florida clinic, where it will be used to deliver high-precision, image-guided Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions. "Being selected as the first commercial site for Zeta's FDA-cleared TMS Navigation System validates the integrated treatment model we are building at HOPE," said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics. "Zeta's AI-driven image guidance brings neurosurgical-grade targeting precision into our outpatient clinics, and it sets the stage for our planned trial of NRX-101 in combination with robotic-enabled TMS in patients with depression and suicidality." TMS is a non-invasive therapy widely used for treatment-resistant depression, which affects approximately one-third of patients with major depression. The clinical efficacy of TMS depends heavily on the accurate targeting of specific neural circuits. The Zeta TMS Navigation System uses proprietary RealTrack™ computer vision and artificial intelligence to continuously align a patient's MRI or CT scan with their facial anatomy in real time, delivering sub-millimetric precision and reducing setup times to under two minutes per session without the need for conventional fiducial markers. The deployment complements HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato® delivery, TMS, Hyperbaric Oxygen Therapy, and other neuroplastic therapies offered across the HOPE network of clinics. It also aligns with NRx's previously announced clinical trial program of NRX-101 (oral D-cycloserine/lurasidone) in combination with robotic-enabled TMS for patients with depression and suicidality, which is planned to be conducted across a leading US academic teaching hospital, three HOPE Therapeutics clinics, and two military treatment facilities. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetic stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve remission from treatment-resistant depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com